Brooke Story Sells 2,300 Shares of LivaNova (NASDAQ:LIVN) Stock

LivaNova PLC (NASDAQ:LIVN) Director Brooke Story sold 2,300 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director owned 7,488 shares of the company’s stock, valued at $609,672.96. This trade represents a 23.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

LivaNova Stock Down 1.5%

LIVN stock traded down $1.22 during trading on Tuesday, reaching $80.70. 472,956 shares of the company traded hands, compared to its average volume of 755,599. LivaNova PLC has a 12 month low of $48.82 and a 12 month high of $85.76. The business has a 50 day simple moving average of $80.67 and a 200 day simple moving average of $73.05. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of 23.88 and a beta of 0.87. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.17. The company had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.05 earnings per share. On average, equities research analysts anticipate that LivaNova PLC will post 3.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System lifted its position in LivaNova by 7,996.3% during the 2nd quarter. California State Teachers Retirement System now owns 5,154,505 shares of the company’s stock worth $423,855,000 after acquiring an additional 5,090,840 shares during the period. Millennium Management LLC increased its holdings in shares of LivaNova by 17.3% in the fourth quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock valued at $214,376,000 after purchasing an additional 514,268 shares during the period. Wellington Management Group LLP increased its holdings in shares of LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after purchasing an additional 1,067,349 shares during the period. Vanguard Group Inc. raised its stake in shares of LivaNova by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after purchasing an additional 34,812 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of LivaNova by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock worth $132,606,000 after purchasing an additional 496,165 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LIVN. KeyCorp upped their target price on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, June 22nd. Zacks Research lowered LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Needham & Company LLC increased their price objective on shares of LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, August 18th. Finally, Freedom Capital upgraded shares of LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $84.12.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.